Reply: “Entering a new GALAXI: The importance of long-term data in Crohn’s disease clinical trials”
Inflammatory Bowel Diseases · 01.07.2026 · 32 (7) · 1428-1429
DOI: 10.1093/ibd/izag082 ↗Kurz gefasst
Editorial in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 15.05.2026. Verfasst von Anita Afzali und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of Cincinnati College of Medicine, Cincinnati, OH, United States. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
- Johnson & Johnson, Antwerp, Belgium.
ORCID-Profile: Anita Afzali, Rian Van Rampelbergh
Förderung
- Johnson & Johnson
Zitieren
APA
Afzali, A., & Van Rampelbergh, R. (2026). Reply: “Entering a new GALAXI: The importance of long-term data in Crohn’s disease clinical trials”. Inflammatory Bowel Diseases, 32(7), 1428-1429. https://doi.org/10.1093/ibd/izag082
Vancouver
Afzali A, Van Rampelbergh R. Reply: “Entering a new GALAXI: The importance of long-term data in Crohn’s disease clinical trials”. Inflammatory Bowel Diseases. 2026;32(7):1428-1429. doi:10.1093/ibd/izag082
BibTeX
@article{Afzali2026,
author = {Afzali, Anita and Van Rampelbergh, Rian},
title = {Reply: “Entering a new GALAXI: The importance of long-term data in Crohn’s disease clinical trials”},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {7},
pages = {1428--1429},
doi = {10.1093/ibd/izag082}
}
EUVIMED